BACKGROUND: Standard care in severe SARS-CoV-2 pneumonia complicated by severe dyspnea and respiratory failure, consists of symptom reduction, ultimately supported by mechanical ventilation. Patients with severe SARS-CoV-2, a prominent feature of COVID-19, show several similar symptoms to Critical Asthma Syndrome (CAS) patients, such as pulmonary edema, mucus plugging of distal airways, decreased tissue oxygenation, (emergent) exhaustion due to severe dyspnea and respiratory failure. Prior application of elective phosphodiesterase (PDE)3-inhibitors milrinone and enoximone in patients with CAS yielded rapid symptomatic relief and reverted the need for mechanical ventilation, due to their bronchodilator and anti-inflammatory properties. Based on these observations, we hypothesized that enoximone may be beneficial in the treatment of patients with severe SARS-CoV-2 pneumonia and prominent CAS-features. METHODS: In this case report enoximone was administered to four consecutive patients (1 M; 3 F; 46-70 y) with emergent respiratory failure due to SARS-CoV-2 pneumonia. Clinical outcome was compared with three controls who received standard care only. RESULTS: After an intravenous bolus of enoximone 20 mg followed by 10 mg/h via perfusor, a rapid symptomatic relief was observed: two out of four patients recovered within a few hours, the other two (with comorbid COPD GOLD II/III) responded within 24-36 h. Compared to the controls, in the enoximone-treated patients respiratory failure and further COVID-19-related deterioration was reverted and mechanical ventilation was prevented, leading to reduced hospital/ICU time. DISCUSSION: Our preliminary observations suggest that early intervention with the selective PDE3-inhibitor enoximone may help to revert respiratory failure as well as avert mechanical ventilation, and reduces ICU/hospital time in patients with severe SARS-CoV-2 pneumonia. Our findings warrant further research on the therapeutic potential of PDE3-inhibition, alone or in combination with other anti-COVID-19 strategies.

Almere The Netherlands

Consultants in Quantitative Methods Eindhoven Netherlands

Department of Pulmonary Medicine Erasmus Medical Centre Rotterdam The Netherlands

Dept of Clinical Pharmacy and Pharmacology UMCG Groningen The Netherlands

Dept of Respiratory Diseases Thomayer Hospital Charles University Prague Czech Republic

Dept of Respiratory Medicine and Allergology Institute for Clinical Science Skane University Hospital Lund Sweden

Mbrace Pharma BV Zeewolde The Neterlands

Rode Kruis Ziekenhuis Beverwijk The Netherlands

See more in PubMed

Chen N, Zhou M, Dong X, et al. . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7. PubMed DOI PMC

Bermejo JF, Munoz-Fernandez MA.. Severe acute respiratory syndrome, a pathological immune response to the new coronavirus-implications for understanding of pathogenesis, therapy, design of vaccines, and epidemiology. Viral Immunol. 2004;17(4):535–544. doi:10.1089/vim.2004.17.535. PubMed DOI

Kenyon N, Zeki AA, Albertson TE, Louie S.. Definition of critical asthma syndromes. Clin Rev Allergy Immunol. 2015;48(1):1–6. doi:10.1007/s12016-013-8395-6. PubMed DOI PMC

Kritas SK, Ronconi G, Caraffa A, Gallenga CE, Ross R, Conti P.. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents. 2020; 34(1): 9–14. doi:10.23812/20-Editorial-Kritas. PubMed DOI

Beute J. Emergency treatment of status asthmaticus with enoximone. Br J Anaesth. 2014;112(6):1105–1108. doi:10.1093/bja/aeu048. PubMed DOI

Schulz O, Wiesner O, Welte T, et al. . Enoximone in status asthmaticus. ERJ Open Res. 2020;6(1):00367–2019. doi:10.1183/23120541.00367-2019. PubMed DOI PMC

Sobhy A, Eldin DMK, Zaki HV.. The use of milrinone versus conventional treatment for the management of life-threatening bronchial asthma. TOATJ. 2019;13(1):12–17. doi:10.2174/2589645801913010012. DOI

Leeman M, Lejeune P, Melot C, Naeije R.. Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD. Chest. 1987;91(5):662–666. doi:10.1378/chest.91.5.662. PubMed DOI

Franciosi LG, Diamant Z, Banner KH, et al. . Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1(9):714–727. doi:10.1016/S2213-2600(13)70187-5. PubMed DOI

Beute J, Lukkes M, Koekoek EP, et al. . A pathophysiological role of PDE3 in allergic airway inflammation. JCI Insight. 2018;3(2)doi:10.1172/jci.insight.94888. PubMed DOI PMC

Santarpino G, Caroleo S, Onorati F, et al. . Inflammatory response to cardiopulmonary bypass with enoximone or steroids in patients undergoing myocardial revascularization: a preliminary report study. CP. 2009;47(02):78–88. doi:10.5414/CPP47078. PubMed DOI

Svensjo E, Andersson KE, Bouskela E, Cyrino FZ, Lindgren S.. Effects of two vasodilatory phosphodiesterase inhibitors on bradykinin-induced permeability increase in the hamster cheek pouch. Agents Actions. 1993;39(1-2):35–41. doi:10.1007/BF01975712. PubMed DOI

Wright LC, Seybold J, Robichaud A, Adcock IM, Barnes PJ.. Phosphodiesterase expression in human epithelial cells. Am J Physiol. 1998;275(4):L694–700. doi:10.1152/ajplung.1998.275.4.L694. PubMed DOI

Surapisitchat J, Beavo JA.. Regulation of endothelial barrier function by cyclic nucleotides: the role of phosphodiesterases. Handb Exp Pharmacol. 2011;(204):193–210. doi:10.1007/978-3-642-17969-3_8 PubMed DOI PMC

Chi CY, Khanh TH, Thoa Le PK, et al. . Milrinone therapy for enterovirus 71-induced pulmonary edema and/or neurogenic shock in children: a randomized controlled trial. Crit Care Med. 2013; 41(7):1754–1760. doi:10.1097/CCM.0b013e31828a2a85. PubMed DOI

Beute J. (Oral) Enoximone in asthma. ERJ Open Res. 2020;6(4):00319–2020. doi:10.1183/23120541.00319-2020. PubMed DOI PMC

Kereiakes D, Chatterjee K, Parmley WW, et al. . Intravenous and oral MDL 17043 (A new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patients. J Am Coll Cardiol. 1984;4(5):884–889. doi:10.1016/S0735-1097(84)80047-9. PubMed DOI

Metra M, Eichhorn E, Abraham WT, et al. . Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009;30(24):3015–3026. doi:10.1093/eurheartj/ehp338. PubMed DOI PMC

Furck AK, Bentley S, Bartsota M, Rigby ML, Slavik Z.. Oral Enoximone as an Alternative to Protracted Intravenous Medication in Severe Pediatric Myocardial Failure. Pediatr Cardiol. 2016; 37(7):1297–1301. doi:10.1007/s00246-016-1433-4. PubMed DOI

Londino JD, Lazrak A, Collawn JF, Bebok Z, Harrod KS, Matalon S.. Influenza virus infection alters ion channel function of airway and alveolar cells: mechanisms and physiological sequelae. Am J Physiol Lung Cell Mol Physiol. 2017;313(5):L845–L58. doi:10.1152/ajplung.00244.2017. PubMed DOI PMC

Liu S, Yu C, Yang F, Paganini-Hill A, Fisher MJ.. Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties. J Neurol Sci. 2012;320(1-2):45–51. doi:10.1016/j.jns.2012.06.005. PubMed DOI PMC

Kosutova P, Mikolka P, Balentova S, Adamkov M, Calkovska A, Mokra D.. Effects of PDE3 inhibitor olprinone on the respiratory parameters, inflammation, and apoptosis in an experimental model of acute respiratory distress syndrome. Int J Mol Sci. 2020; 21(9).doi:10.3390/ijms21093382. PubMed DOI PMC

Cervin A, Lindgren S.. The effect of selective phosphodiesterase inhibitors on mucociliary activity in the upper and lower airways in vitro. Auris Nasus Larynx. 1998;25(3):269–276. doi:10.1016/S0385-8146(98)00010-8. PubMed DOI

Penmatsa H, Zhang W, Yarlagadda S, et al. . Compartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. Mol Biol Cell. 2010;21(6):1097–1110. doi:10.1091/mbc.e09-08-0655. PubMed DOI PMC

Liu S, Veilleux A, Zhang L, et al. . Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J Pharmacol Exp Ther. 2005;314(2):846–854. doi:10.1124/jpet.105.083519. PubMed DOI

Beute J, Ganesh K, Nastiti H, et al. . PDE3 inhibition reduces epithelial mast cell numbers in allergic airway inflammation and attenuates degranulation of basophils and mast cells. Front Pharmacol. 2020;11(470).doi:10.3389/fphar.2020.00470. PubMed DOI PMC

Diamant Z, Timmers MC, van der Veen H, Booms P, Sont JK, Sterk PJ.. Effect of an inhaled neutral endopeptidase inhibitor, thiorphan, on airway responsiveness to leukotriene D4 in normal and asthmatic subjects. Eur Respir J. 1994;7(3):459–466. doi:10.1183/09031936.94.07030459. PubMed DOI

Ding S, Zhang J, Yin S, et al. . Inflammatory cytokines tumour necrosis factor-α and interleukin-8 enhance airway smooth muscle contraction by increasing L-type Ca2+ channel expression. Clin Exp Pharmacol Physiol. 2019; 46(1):56–64. doi:10.1111/1440-1681.13030. PubMed DOI

Horby P, Lim WS, et al. . Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020.doi:10.1056/NEJMoa2021436. PubMed DOI PMC

Giorgi M, Cardarelli S, Ragusa F, et al. . Phosphodiesterase inhibitors: Could they be beneficial for the treatment of COVID-19? Int J Mol Sci. 2020; 21(15): 5338.doi:10.3390/ijms21155338 PubMed DOI PMC

Dalamaga M, Karampela I, Mantzoros CS.. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Covid-19 in Metabolism. 2020;109(154282). doi:10.1016/j.metabol.2020.154282. PubMed DOI PMC

Santaniello A, Vigone B, Beretta L.. Letter to the editor: Immunomodulation by phosphodiesterase-4 inhibitor in COVID-19 patients. Metabolism - Metabolism. 2020;110:154300. VolOpen AccessPublished:June 20, doi:10.1016/j.metabol.2020.154300. PubMed DOI PMC

Hameid RA, Cormet-Boyaka E, Kuebler WM, Uddin M, Berdiev BK.. SARS-CoV-2 may hijack GPCR signaling pathways to dysregulate lung ion and fluid transport. Am J Physiol Lung Cell Mol Physiol. 2021. doi:10.1152/ajplung.00499.2020. PubMed DOI PMC